MarketLONDON · Event November 4, 2026
AstraZeneca reportedly offers ~$10B for Rhythm
The Wall Street Journal first reported an approach. Reuters later described a non-binding proposal of up to $134 a share including milestones. Rhythm shares closed up 28% at $110.68.
AstraZeneca has made a reported, non-binding offer of about $10 billion to acquire Rhythm Pharmaceuticals, the Boston-based maker of the peptide obesity drug IMCIVREE (setmelanotide), according to a Reuters report carried on Investing.com on November 4, 2026. Neither company has announced an agreed transaction.
Reuters attributed the account to three people familiar with the matter. The story should be read as an unconfirmed report of a proposal, not as a signed deal.
What Reuters and the Journal reported
Those people told Reuters that AstraZeneca offered as much as $134 a share in the non-binding proposal, including payments for milestone achievements. Reuters said the Wall Street Journal had reported earlier the same day that AstraZeneca made a $124-per-share offer last month.
Rhythm shares closed up 28% at $110.68 on the news, giving the company a market capitalization of about $7.64 billion, Reuters said. An Investing.com market note on the same day likewise said shares surged 28% after the Journal’s report and closed at $110.68.
Two of Reuters’ sources said the acquisition would be pursued through AstraZeneca’s rare-disease business Alexion, which AstraZeneca acquired for $39 billion in 2021. An AstraZeneca spokesperson declined to comment. Representatives for Rhythm did not respond to Reuters’ request for comment.
The Wall Street Journal, as summarized by Reuters, also said AstraZeneca had previously expressed interest in Rhythm and renewed its pursuit in recent months. Amino Wire has not independently verified the Journal’s original report beyond that Reuters attribution.
Why Rhythm is in the obesity conversation
Rhythm develops therapies for rare neuroendocrine and metabolic disorders, including severe obesity. Its lead commercial product is IMCIVREE, a daily injectable melanocortin-4 receptor (MC4R) agonist.
In March 2026, the U.S. Food and Drug Administration expanded IMCIVREE’s indication to acquired hypothalamic obesity in adults and pediatric patients aged 4 years and older. Rhythm’s March 19, 2026 GlobeNewswire release called it the first and only FDA-approved therapy for that condition. Reuters likewise noted that the March expansion made Imcivree the first U.S.-approved treatment for obesity caused by brain damage of that kind.
That label expansion is a verified company and regulatory fact. It is separate from today’s M&A report: the March approval does not confirm that AstraZeneca will buy Rhythm, and the Reuters proposal does not change IMCIVREE’s approved uses.
What is not known
- Whether a deal will be signed. Reuters described a non-binding proposal. There is no public confirmation from either company that talks have produced an agreement, a revised bid, or a walk-away.
- Final economics. The reported $134 per-share figure includes milestone payments. How much would be paid upfront, and which milestones would apply, is not public.
- Alexion’s role beyond the report. Two Reuters sources said Alexion would pursue the acquisition. AstraZeneca has not said so on the record.
- Rhythm’s response. The company did not comment to Reuters. It has not issued a statement Amino Wire could locate that confirms or denies the approach.
This story summarizes secondary reporting of an unconfirmed proposal and previously announced labeling facts. It is not investment advice.
What changed: key dates
| Date | What happened |
|---|---|
| Rhythm Pharmaceuticals (via GlobeNewswire): Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE (setmelanotide) for Patients with Acquired Hypothalamic Obesity | |
| Reuters (via Investing.com): AstraZeneca made $10 billion offer for obesity drugmaker Rhythm, sources say | |
| Investing.com: Rhythm Pharmaceuticals stock surges 28% on AstraZeneca bid report | |
| Event date for this report | |
| Amino Wire published this report |
Frequently asked questions
Has either company confirmed a deal?
No. Reuters said an AstraZeneca spokesperson declined to comment and that Rhythm representatives did not respond. The proposal was described as non-binding.
What is IMCIVREE?
IMCIVREE (setmelanotide) is Rhythm's melanocortin-4 receptor agonist. In March 2026, FDA expanded its U.S. indication to acquired hypothalamic obesity in patients aged 4 years and older, which Rhythm described as the first FDA-approved therapy for that condition.
Who first reported the approach?
The Wall Street Journal reported first on November 4, 2026. Reuters followed with additional detail attributed to three people familiar with the matter.
Sources
3 linked records- [1] AstraZeneca made $10 billion offer for obesity drugmaker Rhythm, sources say
Reuters (via Investing.com) ·
- [2]
- [3] Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE (setmelanotide) for Patients with Acquired Hypothalamic Obesity
-- First and only FDA-approved therapy for the treatment of acquired hypothalamic obesity, a rare disease characterized by accelerated and sustained weight...
Rhythm Pharmaceuticals (via GlobeNewswire) · Primary record
Amino Wire reports regulatory and court records. Nothing here is medical or legal advice, and we do not provide dosing information. Named companies may respond; see right of reply.
